Patents by Inventor Markus Robert Latta

Markus Robert Latta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230220398
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: January 6, 2023
    Publication date: July 13, 2023
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Patent number: 11578329
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 14, 2023
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Publication number: 20220340912
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: April 19, 2022
    Publication date: October 27, 2022
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen